Fatty Liver Disease in Australia — Diagnosis, Symptoms and Monitoring Guide (2026)

MASLD is a condition in which excess fat accumulates in liver cells in the absence of significant alcohol consumption. The condition is closely linked to metabolic risk factors — obesity, type 2 diabetes, high blood pressure, high triglycerides, and insulin resistance.

MASLD exists on a spectrum:

Simple steatosis: Fat accumulates in liver cells without significant inflammation. This stage is reversible with lifestyle changes and weight loss. Most people at this stage have no symptoms and no significant long-term liver risk.

MASH (metabolic dysfunction-associated steatohepatitis): Inflammation develops alongside fat accumulation. This was previously called NASH (non-alcoholic steatohepatitis). MASH carries a risk of progressive fibrosis and, if untreated, can progress to cirrhosis and liver failure.

Fibrosis: Scarring develops as the liver attempts to repair inflammatory damage. Fibrosis is staged from F0 (no scarring) to F4 (cirrhosis). The presence and degree of fibrosis is the most important prognostic factor in MASLD.

Cirrhosis (F4): Advanced, irreversible scarring that impairs liver function. Cirrhosis carries significant risks including portal hypertension, liver failure, and hepatocellular carcinoma.

MASLD is one of the leading causes of hepatocellular carcinoma, cirrhosis and liver transplantation in the developed world — the first cause of cirrhosis and liver transplantation in women in the USA and the second in men.

MASLD affects approximately 30% of the Australian adult population — roughly 7.8 million Australians. Among specific high-risk groups, prevalence is substantially higher:

• Adults with type 2 diabetes: 65–75% have MASLD
• Adults with obesity (BMI above 30): 60–80% have MASLD
• Adults on GLP-1 medications (Ozempic, Wegovy, Mounjaro): the majority meet the metabolic criteria that predict MASLD

Of those with MASLD, approximately 20% have MASH — the inflammatory form — and approximately 5% have significant fibrosis (F2 or above). Across the Australian population, this translates to roughly 390,000 people with moderate to advanced liver fibrosis who may not know they have it.

MASLD has been Australia's most rapidly growing cause of liver transplantation for over a decade. The GLP-1 era — with hundreds of thousands of Australians now on semaglutide and tirzepatide — creates a new clinical imperative to identify these patients and monitor their liver health.

One of the most clinically challenging aspects of MASLD is that it is frequently asymptomatic in its early stages. Most Australians with simple steatosis and early MASH have no symptoms whatsoever and are diagnosed incidentally — either on a routine blood test showing elevated liver enzymes or on an abdominal ultrasound performed for an unrelated reason.

When symptoms do occur, they typically indicate more advanced disease:

Fatigue: Persistent, unexplained tiredness is the most common symptom of MASLD. It is non-specific — present in many conditions — but in the context of metabolic risk factors it warrants liver assessment.

Right upper quadrant discomfort: A dull ache or sense of heaviness under the right ribcage may reflect liver enlargement (hepatomegaly) from fat accumulation. Not all patients with MASLD have a palpably enlarged liver.

Abdominal bloating: Often associated with metabolic syndrome generally, rather than specific to MASLD.

Symptoms that indicate advanced disease requiring urgent review:

• Jaundice (yellowing of the skin or eyes)
• Dark urine
• Pale or clay-coloured stools
• Swollen abdomen (ascites)
• Easy bruising or bleeding
• Confusion or personality changes (hepatic encephalopathy)

These symptoms suggest decompensated cirrhosis and require urgent specialist review.

The Medical Journal of Australia published a consensus statement in September 2025 recommending systematic MASLD screening for the following groups in primary care:

• All adults with type 2 diabetes
• All adults with obesity (BMI above 30)
• Adults who are overweight (BMI 25–30) with at least one additional metabolic risk factor: hypertension, dyslipidaemia, pre-diabetes, or metabolic syndrome
• Adults with persistently elevated liver enzymes (ALT, AST, GGT) without an identified cause
• Adults on GLP-1 medications for weight management or diabetes

The recommended screening tool is the FIB-4 score — calculated from age, ALT, AST, and platelets available from a routine blood panel. This is a free, non-invasive calculation that stratifies patients into low, indeterminate, and high-risk groups for significant liver fibrosis.

The FIB-4 score is calculated as follows:

FIB-4 = (Age × AST) ÷ (Platelets × √ALT)

Where age is in years, AST and ALT are in U/L, and platelets are in 10⁹/L.

Interpreting your FIB-4 score:

A score below 1.3 indicates low risk of advanced fibrosis. Routine monitoring in primary care, repeat FIB-4 in 3 years.

A score between 1.3 and 2.67 is indeterminate — this is where most patients with MASLD who need further investigation land. The MJA consensus recommends second-line assessment with liver elastography (FibroScan or equivalent) for this group.

A score above 2.67 indicates high risk of advanced fibrosis. Referral to a hepatologist or gastroenterologist is recommended.

If you do not know your FIB-4 score, ask your GP to calculate it at your next blood test — ALT, AST, and platelets are part of a standard metabolic panel.

Liver Elastography (FibroScan)

Liver elastography is the current gold standard non-invasive test for liver fibrosis assessment in Australia. It measures liver stiffness in kilopascals (kPa) and liver fat content (CAP score in dB/m) in a single 10–15 minute session.

Liver fibrosis is the primary determinant of adverse outcomes in MASLD patients, underscoring the importance of its early and accurate detection. While liver biopsy remains the gold standard for fibrosis staging, its invasive nature and high cost render it unsuitable for routine clinical use.

Liver stiffness below 8 kPa: F0–F1, reassuring. Liver stiffness 8–10 kPa: F2, warrants specialist review. Liver stiffness above 13 kPa: F4 range, urgent referral.

Blood Tests and FIB-4

As described above — the FIB-4 score from routine bloods is the first-line screening tool in Australian guidelines. Liver function tests (ALT, AST, GGT, ALP, bilirubin, albumin) plus platelets are standard.

Liver Biopsy

Liver biopsy remains the diagnostic gold standard — it is the only test that can definitively stage fibrosis and confirm MASH histologically. However, it is invasive, carries a small risk of serious complications (1 in 1,000 significant adverse events), requires hospitalisation or day procedure admission, and is subject to sampling error given the liver's size. It is reserved for cases where non-invasive tests are inconclusive or where the diagnosis will materially change management.

Ultrasound

Standard abdominal ultrasound can detect hepatic steatosis — the liver appears brighter than normal — but cannot quantify fibrosis. An ultrasound that shows a bright or echogenic liver confirms fat is present but tells you nothing about whether scarring has developed. It is not a substitute for elastography in MASLD staging.

Lifestyle modification

Weight loss of 7–10% of body weight significantly improves MASLD. For many patients with early steatosis, sustained weight loss through diet and exercise is sufficient to reverse fat accumulation. Weight loss of more than 10% can achieve MASH resolution in a significant proportion of patients.

GLP-1 medications

Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro) produce substantial weight loss and have demonstrated direct liver benefits in clinical trials. Since April 2026, Wegovy has TGA approval for MASH with moderate to advanced fibrosis (F2–F3). This is the most significant pharmacological advance in MASLD treatment in Australian clinical history.

Other medications

Resmetirom (approved in the US in March 2024 for MASH) is under evaluation for TGA approval in Australia. Other agents including vitamin E and pioglitazone have evidence in specific patient groups. Discuss with a hepatologist.

Specialist review

Patients with significant fibrosis (F2 or above), MASH confirmed on biopsy or elastography, or any features suggesting disease progression should be under the care of a hepatologist or gastroenterologist.

If you have risk factors for MASLD and want an elastography assessment, or your GP has referred you for a FibroScan, the Elastography Australia directory lists liver elastography clinics and specialists across all Australian states and territories.

Find a liver elastography clinic or specialist near you →